Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2021 Filed May 13, 2021 20:33 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,157 | $52.60 | $60,861.67 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,482 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.185 to $53.180, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:33 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 379 | $51.63 | $19,567.01 |
DisclosureSEC source: 0001447362-21-000116 · wf-form4_162093800831488.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,639 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $51.110 to $52.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,442 | $69.37 | $169,406.42 |
DisclosureSEC source: 0001447362-21-000101 · wf-form4_161972726245517.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,018 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.090 to $69.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,166 | $68.72 | $561,167.52 |
DisclosureSEC source: 0001447362-21-000101 · wf-form4_161972726245517.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,460 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $68.085 to $69.075, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,766 | $67.38 | $253,738.02 |
DisclosureSEC source: 0001447362-21-000101 · wf-form4_161972726245517.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,626 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.040 to $68.035, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,904 | $71.35 | $207,185.88 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,392 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $71.050 to $71.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 11,470 | $70.76 | $811,594.26 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,296 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $70.050 to $71.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,782 | $70.06 | $405,098.48 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,766 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.850 to $70.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,993 | $69.30 | $138,118.89 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,548 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $68.845 to $69.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,599 | $68.34 | $450,982.26 |
DisclosureSEC source: 0001447362-21-000099 · wf-form4_161964101666972.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,541 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.840 to $68.770, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $69.63 | $34,815.00 |
DisclosureSEC source: 0001447362-21-000091 · wf-form4_161886281589883.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,140 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.36 to $69.80, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,019 | $68.74 | $413,746.06 |
DisclosureSEC source: 0001447362-21-000091 · wf-form4_161886281589883.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,640 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $68.33 to $69.31, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 7,855 | $68.02 | $534,297.10 |
DisclosureSEC source: 0001447362-21-000091 · wf-form4_161886281589883.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,659 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.33 to $68.32, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 308 | $71.69 | $22,078.98 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,514 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $71.680 to $71.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,100 | $71.19 | $291,862.60 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,822 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $70.670 to $71.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,970 | $70.20 | $489,280.06 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,922 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $69.640 to $70.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,996 | $68.82 | $206,187.72 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,892 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $68.470 to $69.410, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,200 | $69.41 | $83,296.80 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,888 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $69.190 to $69.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,302 | $68.51 | $431,731.11 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,088 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $68.190 to $69.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,611 | $67.69 | $244,421.37 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,390 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $67.145 to $68.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,261 | $66.58 | $217,130.42 |
DisclosureSEC source: 0001447362-21-000077 · wf-form4_161851738006629.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,001 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $66.140 to $67.060, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,438 | $61.92 | $584,410.40 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,262 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $61.600 to $62.350, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,114 | $60.99 | $250,916.97 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,700 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $60.590 to $61.580, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 700 | $59.94 | $41,954.50 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,814 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.480 to $60.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,300 | $58.57 | $76,134.50 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,514 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.100 to $58.945, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,322 | $56.99 | $75,336.81 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,814 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $56.690 to $57.500, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,734 | $59.55 | $103,264.90 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,136 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $59.340 to $60.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 11,240 | $58.85 | $661,462.76 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,870 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $58.270 to $59.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $61.91 | $18,572.10 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,110 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $61.860 to $61.930, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,200 | $61.19 | $379,371.80 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,410 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $60.830 to $61.750, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,800 | $60.42 | $108,759.60 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,610 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.800 to $60.795, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,975 | $59.46 | $295,833.40 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,410 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.800 to $59.790, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 59 | $67.03 | $3,955.01 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,385 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.800 to $67.075, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,165 | $66.26 | $77,196.40 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,444 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.800 to $66.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,000 | $65.18 | $130,362.00 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,609 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.800 to $65.620, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,788 | $64.32 | $436,583.80 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,609 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.770 to $64.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,363 | $63.32 | $276,282.61 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,397 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.720 to $63.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 800 | $68.55 | $54,838.40 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,760 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $68.290 to $68.880, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,394 | $67.78 | $636,715.93 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,560 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.280 to $68.240, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,181 | $66.96 | $279,938.86 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,954 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.280 to $67.235, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,685 | $66.22 | $244,009.65 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,135 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.930 to $66.820, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,690 | $65.60 | $373,269.69 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,820 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.920 to $65.900, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,815 | $64.32 | $116,740.80 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,510 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.880 to $64.870, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,185 | $63.26 | $201,495.84 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,325 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.800 to $63.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 110 | $76.77 | $8,444.48 |
DisclosureSEC source: 0001447362-21-000034 · wf-form4_161463406205662.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,510 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $76.600 to $76.855, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,131 | $76.13 | $466,746.90 |
DisclosureSEC source: 0001447362-21-000034 · wf-form4_161463406205662.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,620 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $75.485 to $76.450, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,204 | $75.03 | $390,476.94 |
DisclosureSEC source: 0001447362-21-000034 · wf-form4_161463406205662.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,751 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $74.470 to $75.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,429 | $73.78 | $105,427.33 |
DisclosureSEC source: 0001447362-21-000034 · wf-form4_161463406205662.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749,955 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $73.175 to $74.110, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 494 | $72.58 | $35,855.01 |
DisclosureSEC source: 0001447362-21-000034 · wf-form4_161463406205662.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751,384 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.095 to $72.980, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,007 | $71.10 | $71,600.72 |
DisclosureSEC source: 0001447362-21-000034 · wf-form4_161463406205662.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751,878 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.800 to $71.530, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.